-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on ResMed, Raises Price Target to $321

Benzinga·05/01/2026 17:21:10
Listen to the news
RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Outperform and raises the price target from $314 to $321.